FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I) is a single or double bond, as valence allows; A has formula (A-1) or formula (A-2), where attachment point is in G1 or G2 in formula (A-1) and attachment point is in G2 or G3 in formula (A-2); G1 is N, NRN1 or CRG1, as valence allows; G2 is N or -C=N-, as valence allows; G3 is N or CRG3, as valence allows; G4 is N or CRG4, as valence allows; G5 is N or CRG5, as valence allows; G6 is N or CRG6, as valence allows; and G7 is N or CRG7, as valence allows; in each case RG1, RG2, RG3, RG4, RG5, RG6 and RG7 independently represents hydrogen, halogen, -CN, -ORGA or unsubstituted C1-6 alkyl; in each case RN1 is unsubstituted C1-6 alkyl; in each case RGA independently represents hydrogen, C1-6 alkyl substituted with fluorine or unsubstituted C1-6 alkyl; R1 is C1-6 alkyl substituted with fluorine, methoxy or ethoxy, or unsubstituted C1-6 alkyl; R2 is hydrogen; R3a is hydrogen and R3b is hydrogen; each R4a or R4b independently represents hydrogen; provided that if the bond p is a double bond, then the bond q is a single bond, provided that if the bond q is a double bond, then the bond p is a single bond and R4b is absent; and provided that both bonds q and p are single bonds, hydrogen in C5 is in alpha or beta configuration. Invention also refers to pharmaceutical salts of compounds, to a pharmaceutical composition, to individual compounds and their pharmaceutically acceptable salts.
,
(A-1),
(A-2).
EFFECT: obtaining novel compounds of formula (I), having the GABA modulator property.
21 cl, 13 dwg, 3 tbl, 95 ex
Title | Year | Author | Number |
---|---|---|---|
19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | 2014 |
|
RU2675855C2 |
19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF THEIR USE | 2014 |
|
RU2812930C2 |
COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES OF CENTRAL NERVOUS SYSTEM | 2018 |
|
RU2810331C2 |
COMPOSITIONS AND METHODS OF THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | 2018 |
|
RU2799448C2 |
NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF | 2015 |
|
RU2699359C2 |
NEUROACTIVE STEROIDS SUBSTITUTED AT POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS | 2019 |
|
RU2796006C2 |
NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF | 2014 |
|
RU2696585C2 |
OXYSTEROLES AND METHODS OF USING THEM | 2016 |
|
RU2742333C2 |
COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | 2015 |
|
RU2733756C2 |
OXYSTEROLS AND THEIR APPLICATION METHODS | 2017 |
|
RU2754130C2 |
Authors
Dates
2019-09-16—Published
2014-04-17—Filed